Trichophyton mentagrophytes Genotype VII and Sexually Transmitted Tinea : An Observational Study in Spain
Descalzo Jorro, Vicente (Universitat Autònoma de Barcelona)
Martín, María Teresa (Hospital Universitari Vall d'Hebron)
Álvarez-López, Patricia (Hospital Universitari Vall d'Hebron)
García Pérez, Jorge N (Hospital Universitari Vall d'Hebron)
Alcázar-Fuoli, Laura (Instituto de Salud Carlos III)
López Pérez, Luis (Hospital Universitari Vall d'Hebron)
Téllez Velasco, David (Hospital Universitari Vall d'Hebron)
Carrillo, Antonio (Hospital Universitari Vall d'Hebron)
Sulleiro Igual, Elena (Hospital Universitari Vall d'Hebron)
Falcó, Vicenç (Hospital Universitari Vall d'Hebron)
Arando, Maider (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Data:	2025
Resum:	Background: In 2019, Trichophyton mentagrophytes genotype VII (TMVII) was identified in Germany as a cause of sexually transmitted tinea. Since 2023, it has been described in men who have sex with men (MSM) in France, Italy, and the United States. No cases have been reported in Spain. Obectives: Our study aimed to assess the occurrence of TMVII in an STI clinic in Barcelona. Patients/Methods: We identified TMVII cases among all positive mycological skin/hair cultures between January 2020 and January 2025 by sequencing the internal transcribed spacer on isolates of T. mentagrophytes-interdigitale. We retrospectively collected demographic, clinical and treatment data and analysed the association between treatment received and outcome (cure vs. recurrence). Results: Among 21 positive cultures, we obtained 15 isolates of T. mentagrophytes-interdigitale, of which 14 were sequenced and identified as TMVII. Patients with TMVII were all MSM; most were HIV positive (7) or negative on preexposure prophylaxis (6). Main sites of infection were pubogenital (6), buttocks-perianal (5) and beard (2). Six patients required multiple courses of treatment due to recurrence. Twenty-one courses of antifungal therapy were analysed, with an observed cure rate of 45% (5/11) for oral terbinafine vs. 80% (7/10) for topical agents (p = 0. 39), and 0% (0/6) for ≤ 2-week courses vs. 80% (12/15) for 3-to-8-week courses (p < 0. 01). Conclusions: Our study confirms the presence of TMVII in Spain, supporting its circulation across Europe. Epidemiological profile and site of infection support sexual transmission. Patients responded to systemic or topical terbinafine but required longer-than-usual periods of treatment.
Nota:	This work was carried out within the frame of the Doctoral Programme in Medicine at the Universitat Autonoma de Barcelona.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Dermatomycosis ; Mycoses ; Sexual health ; Sexually transmitted diseases ; Tinea ; Trichophyton infection ; Trichophyton mentagrophytes ; Venereology
Publicat a:	Mycoses, Vol. 68 Núm. 4 (april 2025) , p. e70049, ISSN 1439-0507

DOI: 10.1111/myc.70049

6 p, 697.3 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats